Ovoca Bio plc
OVB.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | 0.00% | -0.16% | 0.00% | -5.97% |
| EV / EBITDA | 0.00 | 1.90 | -1.52 | -1.29 |
| Quality | ||||
| ROIC | 0.00% | -55.45% | -159.28% | -22.68% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | 1.12 | 0.29 | -24.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 100.00% | 0.00% | 0.00% | 30.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 2.68 | -1.98 | 1.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |